Diffusion Pharmaceuticals

140 articles about Diffusion Pharmaceuticals

• Diffusion Pharmaceuticals Successfully Completes First Cohort in Multicenter Phase I/II Brain Cancer Trial of TSC

  8/2/2012

• Diffusion Pharmaceuticals Receives FDA Orphan Status for TSC, a First-in-Class Drug for the Treatment of Primary Brain Cancer

  7/26/2011

• Diffusion Pharmaceuticals Achieves Positive Results in Phase I/II Clinical Trial of Trans Sodium Crocetinate in Peripheral Artery Disease

  11/16/2010

• Results of Phase I/II Clinical Trial of Diffusion Pharmaceuticals' Trans Sodium Crocetinate in Patients with Peripheral Artery Disease (PAD) to be Presented at American Heart Association Scientific Sessions

  11/15/2010

• Results of Phase I/II Clinical Trial of Diffusion Pharmaceuticals' Trans Sodium Crocetinate in Patients with Peripheral Artery Disease (PAD) to be Presented at American Heart Association Scientific Sessions

  11/10/2010

• Diffusion Pharmaceuticals Announces Issuance of New U.S. Patent

  8/2/2010

• Diffusion Pharmaceuticals Closes on $5.9 Million Financing

  1/29/2010

• Diffusion Pharmaceuticals Announces Addition of Dr. David R. Jones as Chief Medical Officer, and Dr. Guy M. Chisolm Joins its Scientific Advisory Board

  1/6/2010

• Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement

  2/9/2009

• Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)

  9/3/2008

• Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors

  6/11/2008

• Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844

  4/9/2008

• Co-Inventor of Amgen's Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals' First-in-Class Oxygen Enhancing Therapeutics

  12/21/2007

• Diffusion Pharmaceuticals Announces Results of Phase I Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and Completion of a $4.5 Million Private Placement

  9/28/2007

• Diffusion Pharmaceuticals Announces Formation of Scientific Advisory Board Chaired by Company Co-founder, John L. Gainer, Ph.D.

  4/26/2007

• Diffusion Pharmaceuticals Initiates Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC)

  3/16/2007

• Diffusion Pharmaceuticals Strengthens Management Team With Appointment Of Matthew W. Hantzmon As Vice President, Business Development

  11/14/2006

• Diffusion Pharmaceuticals Completes FDA Required Toxicology Studies In Support Of Phase I Trials And Closes $1.5 Million Private Placement

  10/17/2006

• Diffusion Pharmaceuticals Resumes Toxicology Studies With MPI Research; Company Advances Toward Filing Investigational New Drug Application

  2/22/2006

• Tech Council of Maryland Release: Area Life Science Companies Chosen To Make Presentations For Venture Funding At 2005 Mid-Atlantic Bio

  10/12/2005